Citations

Clear

38 citation(s) found for "Scanlon, Paul".

Regulation of ventilatory capacity during exercise in asthmatics
Johnson, B. D., Scanlon, Paul D., Beck, Kenneth C.

Mayo Clinic

Journal of Applied Physiology | December 22, 2017 | Volume: 79 | Issue: 3 | Pages: 892-901

10.1152/jappl.1995.79.3.892 | PMID 8567533 Get It

In asthmatic and control subjects, we examined the changes in ventilatory capacity (VECap), end-expiratory lung volume (EELV), and degree of flow limitation during three types of exercise: 1) incremental, 2) constant load (50% of maximal exercise capacity; 36 min), and 3) interval (alternating between 60 and 40% of maximal exercise capacity; 6-min workloads for 36 min). The VECap and degree of flow limitation at rest and during the various stages of exercise were estimated by aligning the tidal breathing flow-volume (F-V) loops within the maximal expiratory F-V (MEFV) envelope using the measured EELV. In contrast to more usual estimates of VECap (i.e., maximal voluntary ventilation and forced expiratory volume in 1 s x 40), the calculated VECap depended on the existing bronchomotor tone, the lung volume at which the subjects breathed (i.e., EELV), and the tidal volume. During interval and constant-load exercise, asthmatic subjects experienced reduced ventilatory reserve, higher degrees of flow limitation, and had higher EELVs compared with nonasthmatic subjects. During interval exercise, the VECap of the asthmatic subjects increased and decreased with variations in minute ventilation, due in part to alterations in their MEFV curve as exercise intensity varied between 60 and 49% of maximal capacity. In conclusion, asthmatic subjects have a more variable VECap and reduced ventilatory reserve during exercise compared with nonasthmatic subjects. The variations in VECap are due in part to a more labile MEFV curve secondary to changes in bronchomotor tone. Asthmatics defend VECap and minimize flow limitation by increasing EELV.
Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis
Festić, Emir , Bansal, Vikas , Gupta, Ena, Scanlon, Paul D., Bansal, Vikas

Mayo Clinic

COPD: Journal of Chronic Obstructive Pulmonary Disease | December 9, 2015 | Volume: 13 | Issue: 3 | Pages: 312-326

10.3109/15412555.2015.1081162 | PMID 26645797 Get It

Incident Pneumonia and Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Double Effect of Inhaled Corticosteroids?
Festić, Emir , Scanlon, Paul D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | November 19, 2014 | Volume: 191 | Issue: 2 | Pages: 141-148

10.1164/rccm.201409-1654pp | PMID 25409118 Get It

Abstract Inhaled corticosteroids are commonly prescribed for patients with severe chronic obstructive pulmonary disease. Although their use improves quality of life and reduces exacerbations, it is associated with increased risk of pneumonia. Curiously, their use has not been associated with increased risk of pneumonia-related or overall mortality. We review pertinent literature to further explore the effects of inhaled corticosteroids on incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. The association of use of inhaled corticosteroids and incident pneumonia is substantial and has been present in the majority of the studies on the topic. This includes both randomized controlled trials and observational studies. However, all of the studies have substantial risk of bias. Most randomized trials are limited by lack of systematic ascertainment of pneumonia; they depended on adverse event reporting. Many observational studies included proper radiographic assessment of pneumonia, but they are limited by their retrospective, observational design. The unadjusted higher risk of pneumonia is associated with longer duration of use, more potent ICS compounds, and higher doses. That implies a dose–effect relationship. Unlike pneumonia, mortality is a precise outcome. Despite the robust association of inhaled corticosteroid use with increased risk of pneumonia, all studies find either no difference or a reduction in pulmonary-related and overall mortality associated with the use of inhaled corticosteroids. These observations suggest a double effect of inhaled corticosteroids (i.e., an adverse effect plus an unexplained mitigating effect).
Predictors of Chronic Obstructive Pulmonary Disease Exacerbation Reduction in Response to Daily Azithromycin Therapy
Tayob, Nabihah , Murray, Susan , Washko, George R. , Scanlon, Paul D., Casaburi, Richard , Connett, John E. , Lazarus, Stephen C. , Albert, Richard , Woodruff, Prescott G. , Han, MeiLan King , Dransfield, Mark T. , Criner, Gerard J. , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 29, 2014 | Volume: 189 | Issue: 12 | Pages: 1503-1508

10.1164/rccm.201402-0207oc | PMID 24779680 Get It

Abstract Rationale Daily azithromycin decreases acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but long-term side effects are unknown. Objectives To identify the types of exacerbations most likely to be reduced and clinical subgroups most likely to benefit from azithromycin, 250 mg daily, added to usual care. Methods Enrollment criteria included irreversible airflow limitation and AECOPD requiring corticosteroids, emergency department visit, or hospitalization in the prior year or use of supplemental oxygen. Recurrent events and cumulative incidence analyses compared treatment received for AECOPD by randomization group, stratified by subgroups of interest. Cox proportional hazards models estimated treatment effects in subgroups adjusted for age, sex, smoking status, FEV1% predicted, concomitant COPD medications, and oxygen use. Measurements and Main Results Azithromycin was most effective in reducing AECOPD requiring both antibiotic and steroid treatment (n = 1,113; cumulative incidence analysis, P = 0.0002; recurrent events analysis, P = 0.002). No difference in treatment response by sex (P = 0.75), presence of chronic bronchitis (P = 0.19), concomitant inhaled therapy (P = 0.29), or supplemental oxygen use (P = 0.23) was observed. Older age and milder Global Initiative for Chronic Obstructive Lung Disease stage were associated with better treatment response (P = 0.02 and 0.04, respectively). A significant interaction between treatment and current smoking was seen (P = 0.03) and azithromycin did not reduce exacerbations in current smokers (hazard ratio, 0.99; 95% confidence interval, 0.71–1.38; P = 0.95). Conclusions Azithromycin is most effective in preventing AECOPD requiring both antibiotic and steroid treatment. Adjusting for confounders, we saw no difference in efficacy by sex, history of chronic bronchitis, oxygen use, or concomitant COPD therapy. Greater efficacy was seen in older patients and milder Global Initiative for Chronic Obstructive Lung Disease stages. We found little evidence of treatment effect among current smokers. Clinical trial registered with www.clinicaltrials.gov (NCT0011986 and NCT00325897).
A Prospective Study of Chronic Obstructive Pulmonary Disease and the Risk for Mild Cognitive Impairment
Singh, Balwinder , Mielke, Michelle M. , Parsaik, Ajay K. , Cha, Ruth H., Roberts, Rosebud O., Scanlon, Paul D., Geda, Yonas E. , Christianson, Teresa J., Petersen, Ronald C. , Cha, Ruth H., Pankratz, V. Shane , Mielke, Michelle M , Singh, Balwinder , Geda, Yonas E

Mayo Clinic

JAMA Neurology | March 17, 2014 | Volume: 71 | Issue: 5 | Pages: 581

10.1001/jamaneurol.2014.94 | PMID 24637951 Get It

Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations
O’Reilly, Philip, Jackson, Patricia L. , Wells, J. Michael , Scanlon, Paul D., Blalock, J. Edwin , Dransfield, Mark T. , Wells, J Michael

Mayo Clinic

BMJ Open | December 23, 2013 | Volume: 3 | Issue: 12 | Pages: e004140

10.1136/bmjopen-2013-004140 | PMID 24366582 Get It

Rationale Proline–glycine–proline (PGP), a neutrophil chemoattractant derived from the enzymatic breakdown of collagen, is elevated in sputum of patients with chronic obstructive pulmonary disease (COPD) and may contribute to disease progression. Whether sputum levels of PGP respond to therapy for COPD or predict outcomes is unknown. Objectives We conducted a study ancillary to a multicenter trial of the efficacy of azithromycin treatment for 1 year in preventing COPD exacerbations to test whether sputum levels of PGP were altered by treatment or associated with exacerbation frequency. Methods We collected remnant sputa from trial participants and assayed them in a blinded fashion for PGP, myeloperoxidase and matrix metalloproteinase (MMP)-9 and for the ability to generate PGP from collagen ex vivo . Once the parent trial was unblinded, the results were correlated with use of azithromycin or placebo and exacerbations in participants. Results Azithromycin treatment significantly reduced sputum levels of PGP and myeloperoxidase in patients with COPD, particularly with increased duration of therapy. We found no difference in sputum MMP-9 or PGP generation between participants taking azithromycin or placebo. Sputum PGP levels were highest around the time of an exacerbation and declined with successful treatment. Conclusions These data support a role for PGP in the airway and parenchymal neutrophilic inflammation that drives COPD progression and exacerbations, and provide new information on the anti-inflammatory properties of macrolides. PGP may have potential as a target for novel anti-inflammatory therapies in COPD and as a biomarker for clinical trials.
Chronic Airflow Limitation and Obesity
Scanlon, Paul D., Enright, Paul

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 113 | Issue: 12 | Pages: 993-994

10.7326/0003-4819-113-12-993_2 | PMID 2240925 Get It

Bronchoconstriction Occurring During Exercise in Asthmatic Subjects
Beck, Ken C., Offord, K P, Scanlon, Paul D.

Mayo Clinic

American journal of respiratory and critical care medicine | April 4, 2013 | Volume: 149 | Issue: 2 | Pages: 352-357

10.1164/ajrccm.149.2.8306029 | PMID 8306029 Get It

Abstract To demonstrate physiologic changes associated with asthma symptoms that many patients with asthma develop during exercise, we used sustained constant-load and interval exercise protocols with subjects breathing dry room temperature air. In constant-load exercise, subjects pedaled a stationary bicycle at 50% of their maximal power capacity for 36 min. In interval protocols, subjects pedaled at 60% of maximal capacity for 6 min and then 40% of maximal for 6 min; the 12-min cycle was repeated three times for a total exercise time of 36 min. Maximal expiratory flow versus volume maneuvers (MEFV) were obtained before, at 6-min intervals during, and at 5-min intervals after exercise. Changes in peak expiratory flow (PEF), forced expiratory volume in 1 s (FEV1), and forced expiratory flow at 50% of pre-exercise vital capacity (FEF50) were compared with pre-exercise values. Within 15 min after a maximal 1-min incremental exercise protocol, mean flows decreased compared with pre-exercise (PEF, mean -22%, range -46 to 5%; FEV1, mean -21%, range -42 to -3%; FEF50, mean -41%, range -80 to 3%; all p < 0.05). There were no significant changes in MEFV flows until 18 min of constant-load exercise, when FEV1 and FEF50 fell (FEV1, mean -6%, range -15 to 2%; FEF50, mean -14%, range -32 to 6%; both p < 0.05), although changes in PEF were minimal and were not significantly different compared with pre-exercise.(ABSTRACT TRUNCATED AT 250 WORDS)
The Pulmonary Artery Catheter Dilemma
Scanlon, Paul D.

Mayo Clinic

American Review of Respiratory Disease | April 4, 2013 | Volume: 138 | Issue: 2 | Pages: 491-491

10.1164/ajrccm/138.2.491 Get It

Regional Distribution of Diffusible Tracers and Carbonized Microspheres in the Left Ventricle of Isolated Dog Hearts
Yipintsoi, Tada, Dobbs, William A., Scanlon, Paul D., Knopp, T. J., Bassingthwaighte, James B.

Mayo Clinic

Circulation Research | June 12, 2012 | Volume: 33 | Issue: 5 | Pages: 573-587

10.1161/01.res.33.5.573 | PMID 4752857 Get It

Microspheres of different sizes, 125 I-labeled antipyrine (I-Ap), and 42 KCl or 86 RbCl were injected into the aortic inflow of isolated, Langendorff, perfused, nonworking dogs hearts at blood flows of 1.3-4.8 ml/min g -1 . After 15 seconds to 5 minutes, the left ventricle was sectioned into about 300 ordered pieces, and the amount of each tracer was determined. For all tracers, the relative density of deposition was generally higher in the endocardial region, except in one heart in which the aortic pressure and the total coronary flow were low. The deposition of 42 K and that of I-Ap were essentially similar in three hearts over a large range of regional variation. This finding suggests either that both tracers were distributed in proportion to flow or that a small diminution in relative density of deposition of 42 K in high-flow regions due to lower transcapillary extraction was quantitatively similar to a decrease in the residual fraction of I-Ap in these same regions due to faster washout in the first 15-30 seconds after injection. Large microspheres were deposited preferentially in regions of high flow, exaggerating the apparent heterogeneity of regional flows. The distribution of the smaller microspheres was closer to that for I-Ap or 42 K.